日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis

新型抗病毒疗法治疗乙型肝炎病毒的功能性治愈：系统评价和荟萃分析

期刊:Hepatology International
影响因子:6.1
doi:10.1007/s12072-025-10823-5
Chen, Jing; Ji, Dong; Jia, Jidong; Zhuang, Hui; Zhang, Xinxin; Wang, Fu-Sheng; Zhang, Wenhong; Dou, Xiaoguang; Tanwandee, Tawesak; Sarin, Shiv Kumar; Maiwall, Rakhi; Kumar, Manoj; Goh, George Boon-Bee; Ghazinyan, Hasmik; Chutaputti, Anuchit; Chen, Pei-Jer; You, Hong; Yu, Ming-Lung; George, Jacob; Omata, Masao; Wang, Gui-Qiang; Lau, George
微生物学
肝炎
发表日期：2025
文献求助 收藏

Integration of Traditional, Complementary, and Integrative Medicine in the Institutionalization of Evidence-Informed Decision-Making: The World Health Organization Meeting Report

将传统医学、补充医学和综合医学纳入循证决策制度：世界卫生组织会议报告

期刊:Journal of Integrative and Complementary Medicine
影响因子:1.7
doi:10.1089/jicm.2024.0837
Steel, Amie; Gallego-Perez, Daniel F; Ijaz, Nadine; Gall, Alana; Bangpan, Mukdarut; Dos Santos Boeira, Laura; Schveitzer, Mariana Cabral; Chutaputti, Anchalee; Mahlanza-Langer, Laurenz; Pillai, Geetha Krishnan G; Posayanonda, Tipicha; Sungchol, Kim; Shankar, Darshan; Kuchenmüller, Tanja
发表日期：2025
文献求助 收藏

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B

在亚洲HBeAg阳性和HBeAg阴性慢性乙型肝炎患者中，聚乙二醇干扰素α-2a（40 kDa）联合或不联合拉米夫定治疗的持续应答情况

期刊:Hepatology International
影响因子:6.1
doi:10.1007/s12072-007-9022-5
Piratvisuth, Teerha; Lau, George; Chao, You-Chen; Jin, Rui; Chutaputti, Anuchit; Zhang, Q-B; Tanwandee, Tawesak; Button, Peter; Popescu, Matei
肝炎
发表日期：2008
文献求助 收藏